Elotuzumab , an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 ( SLAMF7 ) , showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma .